To implement the relevant spirit of executive meeting of the State Council of China and accelerate the entry of clinically imperative new drugs marketed overseas into China, the National Medical Products Administration (NMPA) and National Health Commission of China organized relevant experts on Mar. 28, 2019 to conduct research and demonstration and select the second batch of clinically imperative overseas new drugs.
